Nkarta to Participate in an Upcoming Investor Conference

11/12/24 8:02:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NKTX alert in real time by email

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

Stifel 2024 Healthcare Conference

November 19, 2024

10:55 a.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at www.nkartatx.com.

Nkarta Media/Investor Contact:

Greg Mann

Nkarta, Inc.

[email protected]

Get the next $NKTX alert in real time by email

Date	Price Target	Rating	Analyst
10/9/2024	$14.00	Buy	Rodman & Renshaw
8/14/2024	$16.00	Outperform → Strong Buy	Raymond James
3/22/2024	$13.00 → $16.00	Strong Buy → Outperform	Raymond James
12/22/2022		Outperform → Perform	Oppenheimer
10/10/2022	$25.00	Buy	Canaccord Genuity
7/28/2022	$26.00	Buy	Needham
7/18/2022	$30.00	Outperform	SVB Leerink
3/11/2022	$17.00	Outperform	Raymond James

Nkarta to Participate in an Upcoming Investor Conference

Chat with this insight

Recent Analyst Ratings for $NKTX

$NKTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Shook David gave a grant of 1,352 shares, decreasing direct ownership by 0.97% to 138,593 units (SEC Form 4)

SEC Form 4 filed by President Mahmood Nadir

New insider Mahmood Nadir claimed ownership of 31,376 shares (SEC Form 3)

$NKTX SEC Filings

SEC Form 10-Q filed by Nkarta Inc.

Nkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: Nkarta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

$NKTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$NKTX Leadership Updates

Live Leadership Updates

$NKTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

$NKTX Financials

Live finance-specific insights

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

$NKTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Nkarta with a new price target

Nkarta upgraded by Raymond James with a new price target

Nkarta downgraded by Raymond James with a new price target

$NKTX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Nkarta, Maintains $23 Price Target

Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis

Nkarta shares are trading higher after the company appointed Nadir Mahmood as President.

$NKTX Press Releases

Fastest customizable press release news feed in the world

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in Upcoming Investor Conference

Recent Analyst Ratings for
$NKTX

$NKTX
Insider Trading

$NKTX
SEC Filings

$NKTX
Insider Purchases

$NKTX
Leadership Updates

$NKTX
Large Ownership Changes

$NKTX
Financials

$NKTX
Analyst Ratings

$NKTX
Market Insights

$NKTX
Press Releases